These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27094354)

  • 81. Studies directed toward the asialoglycoprotein receptor mediated delivery of 5-fluoro-2'-deoxyuridine for hepatocellular carcinoma.
    Rico L; Østergaard ME; Bell M; Seth PP; Hanessian S
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2652-2654. PubMed ID: 30042045
    [TBL] [Abstract][Full Text] [Related]  

  • 82. TRIM28 attenuates Bortezomib sensitivity of hepatocellular carcinoma cells through enhanced proteasome expression.
    Zhang J; Fan X; Liao L; Zhu Y; Wan X; Rao H; Chen L
    Clin Transl Med; 2022 Jan; 12(1):e603. PubMed ID: 35061933
    [No Abstract]   [Full Text] [Related]  

  • 83. Aptamer-Functionalized Drug Nanocarrier Improves Hepatocellular Carcinoma toward Normal by Targeting Neoplastic Hepatocytes.
    Chakraborty S; Dlie ZY; Chakraborty S; Roy S; Mukherjee B; Besra SE; Dewanjee S; Mukherjee A; Ojha PK; Kumar V; Sen R
    Mol Ther Nucleic Acids; 2020 Jun; 20():34-49. PubMed ID: 32146417
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The Application of Aptamer and Research Progress in Liver Disease.
    Xu C; Tan Y; Zhang LY; Luo XJ; Wu JF; Ma L; Deng F
    Mol Biotechnol; 2024 May; 66(5):1000-1018. PubMed ID: 38305844
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The Research Advances of Aptamers in Hematologic Malignancies.
    Liao Y; Xiong S; Ur Rehman Z; He X; Peng H; Liu J; Sun S
    Cancers (Basel); 2023 Jan; 15(1):. PubMed ID: 36612296
    [TBL] [Abstract][Full Text] [Related]  

  • 86. eEF1A1 promotes colorectal cancer progression and predicts poor prognosis of patients.
    Fan AH; Zhao X; Liu H; Li D; Guo T; Zhang J; Duan L; Cheng H; Nie Y; Fan D; Zhao X; Lu Y
    Cancer Med; 2023 Jan; 12(1):513-524. PubMed ID: 35607944
    [TBL] [Abstract][Full Text] [Related]  

  • 87. RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?
    Sartorius K; Antwi SO; Chuturgoon A; Roberts LR; Kramvis A
    Front Oncol; 2022; 12():891812. PubMed ID: 35600358
    [TBL] [Abstract][Full Text] [Related]  

  • 88. High eEF1A1 Protein Levels Mark Aggressive Prostate Cancers and the In Vitro Targeting of eEF1A1 Reveals the eEF1A1-actin Complex as a New Potential Target for Therapy.
    Bosutti A; Dapas B; Grassi G; Bussani R; Zanconati F; Giudici F; Bottin C; Pavan N; Trombetta C; Scaggiante B
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456960
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Expression and Clinical Value of Eukaryotic Translation Elongation Factor 1A1 (EEF1A1) in Diffuse Large B Cell Lymphoma.
    Gong T; Shuang Y
    Int J Gen Med; 2021; 14():7247-7258. PubMed ID: 34737619
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Xenograft Zebrafish Models for the Development of Novel Anti-Hepatocellular Carcinoma Molecules.
    Tonon F; Farra R; Zennaro C; Pozzato G; Truong N; Parisi S; Rizzolio F; Grassi M; Scaggiante B; Zanconati F; Bonazza D; Grassi G; Dapas B
    Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451900
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases.
    Giudice V; Mensitieri F; Izzo V; Filippelli A; Selleri C
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375354
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis.
    Giudici F; Petracci E; Nanni O; Bottin C; Pinamonti M; Zanconati F; Scaggiante B
    PLoS One; 2019; 14(6):e0218030. PubMed ID: 31220107
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Screening therapeutic targets of ribavirin in hepatocellular carcinoma.
    Xu C; Luo L; Yu Y; Zhang Z; Zhang Y; Li H; Cheng Y; Qin H; Zhang X; Ma H; Li Y
    Oncol Lett; 2018 Jun; 15(6):9625-9632. PubMed ID: 29805683
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma.
    Ladju RB; Pascut D; Massi MN; Tiribelli C; Sukowati CHC
    Oncotarget; 2018 Jan; 9(2):2951-2961. PubMed ID: 29416827
    [TBL] [Abstract][Full Text] [Related]  

  • 95. eEF1A1 Overexpression Enhances Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma.
    Chen SL; Lu SX; Liu LL; Wang CH; Yang X; Zhang ZY; Zhang HZ; Yun JP
    Transl Oncol; 2018 Feb; 11(1):125-131. PubMed ID: 29248802
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects.
    Scaggiante B; Farra R; Dapas B; Baj G; Pozzato G; Grassi M; Zanconati F; Grassi G
    Int J Pharm; 2016 Jun; 506(1-2):268-79. PubMed ID: 27094354
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
    Baiz D; Pozzato G; Dapas B; Farra R; Scaggiante B; Grassi M; Uxa L; Giansante C; Zennaro C; Guarnieri G; Grassi G
    Biochimie; 2009 Mar; 91(3):373-82. PubMed ID: 19041685
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The expression levels of the translational factors eEF1A 1/2 correlate with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade.
    Grassi G; Scaggiante B; Farra R; Dapas B; Agostini F; Baiz D; Rosso N; Tiribelli C
    Biochimie; 2007 Dec; 89(12):1544-52. PubMed ID: 17825975
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Rapid and cost-effective xenograft hepatocellular carcinoma model in Zebrafish for drug testing.
    Tonon F; Zennaro C; Dapas B; Carraro M; Mariotti M; Grassi G
    Int J Pharm; 2016 Dec; 515(1-2):583-591. PubMed ID: 27989824
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.